Media & Investors

Media and Investor Information

Financials

Ypsomed has a strong track record of growth with increasing profitability. For the overall year 2016/17, we will increase the outlook for growth in net sales to around 15.0 %. The operating result of around CHF 55.0 million is confirmed.

More facts & figures

Coming events

DateEvent
Place 
November 03, 2016 Press conference and presentation
of the half year results 2016/17, plus publication of semiannual report
Zürich
May 24, 2017 Press conference and presentation
of the annual results 2016/17, plus publication of annual report
Burgdorf Calendar
June 28, 2017 General meeting of Ypsomed Holding AG   Calendar

Investor agenda

Latest News

Ypsomed honoured as successful company with future-oriented work models

Burgdorf, 12 January 2017, 7.00 a.m. – On 11 January 2017, Ypsomed was honoured with the 20th Solothurn Business Award. Ypsomed received an award for their outstanding business performance in the canton of Solothurn in terms of implementing modern work models and for its commitment to promoting the production location in Switzerland. The ceremony was held in front of over 350 attendees representing commerce, politics and administration.

Ypsomed gains a further customer in Russia

Burgdorf, 20 December 2016, 7 a.m. – The human insulin of Russian pharmaceutical company GEROPHARM will in future be administered with a pen from Ypsomed's ServoPen® platform. This is a further confirmation of Ypsomed's platform strategy in the field of injection systems.

Ypsomed continues on its path of growth

Burgdorf, 3 November 2016, 7:00 am – In the first half-year of the current business year 2016/17, the Ypsomed Group generated consolidated net sales of CHF 185.4 million, CHF 27.6 million more than compared with the same period of the previous year (CHF 157.8 million). This represents an increase in sales of 17.5%. In the first half-year of 2016/17, the operating result (EBIT) increased by an impressive 45.0% to CHF 28.1 million compared to the previous year. The EBIT margin is now at 15.2% (previous year: 12.3%). The increase in EBIT is largely due to higher sales and increased utilisation of production capacities, but also to efficiency improvements in production and sales processes. For the reporting period we can post a net profit of CHF 22.4 million.

Ypsomed's ServoPen® for the treatment of Parkinson's disease

Burgdorf, 19 October 2016, 7.00 a.m. – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine® Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen® platform, facilitates subcutaneous administration with its patient friendly design.

New member joins Executive Management in the Ypsomed Group

Michael Zaugg will join the Executive Management of the Ypsomed Group in mid-April 2017 and take on the role of Senior Vice President Human Resources. He will succeed Yvonne Müller, who is leaving Ypsomed at her own request.